𝔖 Bobbio Scriptorium

✦ LIBER ✦

26 INVITED Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience

✍ Scribed by A. Reid; G. Attard; N. Babu Oommen; D. Olmos; P. Fong; R. Molife; M. Dowsett; G. Lee; A. Molina; J.S. De-Bono

Book ID: 119599181
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 61 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)71958-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Selective Inhibition of CYP17 with A

Re: Selective Inhibition of CYP17 with Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

✍ Hans-Peter Schmid; Daniel S. Engeler 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 94 KB

Commentary on Selective inhibition of CY

Commentary on Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer: Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS, Royal Marsden National Health Service Foundation Trust, The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Cougar Biotechnology, Los Angeles, CA

✍ Daniel W. Lin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 85 KB